Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival Curves01:18

Survival Curves

Survival curves are graphical representations that depict the survival experience of a population over time, offering an intuitive way to track the proportion of individuals who remain event-free at each time point. These curves are widely used in fields such as medicine, public health, and reliability engineering to visualize and compare survival probabilities across different groups or conditions.
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
Actuarial Approach01:20

Actuarial Approach

The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Research progress in botany, phytochemistry, pharmacological action, toxicology, and clinical application of genus Serissa: a review.

The Journal of pharmacy and pharmacology·2026
Same author

Stepwise Protocol for Alternative Splicing Analysis in Single-Cell SMART-Seq2 RNA-Seq Data.

Bio-protocol·2026
Same author

BSA@Cu<sub>3</sub>(PO<sub>4</sub>)<sub>2</sub> hybrid nanoflower as bioinspired tyrosinase-mimicking nanozyme for production of amino acid surfactant from caffeate.

Food chemistry·2026
Same author

Vagal nerve innervation divergence in liver/pancreas: A forgotten key to endocrine recovery after transplantation?

World journal of transplantation·2026
Same author

Triggering receptor expressed on myeloid cells 2-driven pancreatic macrophage crosstalk: Key regulator of obesity pathophysiology and metabolic dysregulation.

World journal of biological chemistry·2026
Same author

Childhood Ayme-Gripp syndrome: A case report.

The Journal of international medical research·2026

Related Experiment Video

Updated: Jun 1, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Evaluating markers for treatment selection based on survival time.

Xiao Song1, Xiao-Hua Zhou

  • 1Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia, GA, U.S.A.. xsong@uga.edu

Statistics in Medicine
|May 26, 2011
PubMed
Summary

This study extends the selection impact (SI) curve method to evaluate how biomarkers guide treatment selection for continuous outcomes, like survival time. The new covariate-specific SI curve helps personalize cancer treatment strategies for better patient outcomes.

Related Experiment Videos

Last Updated: Jun 1, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Area of Science:

  • Biostatistics
  • Clinical Trial Methodology
  • Translational Oncology

Background:

  • Multiple treatment options exist for various medical conditions.
  • Biomarkers can guide treatment selection, but existing methods have limitations for continuous outcomes and covariate adjustment.
  • The selection impact (SI) curve is useful for binary outcomes but needs extension.

Purpose of the Study:

  • To extend the selection impact (SI) curve for general and survival outcomes.
  • To propose a covariate-specific SI curve for incorporating patient covariates in treatment selection.
  • To provide tools for quantifying the population-level impact of biomarker-guided treatment selection.

Main Methods:

  • Extension of the selection impact (SI) curve methodology for continuous and survival outcomes.
  • Development of nonparametric and semiparametric estimators for the proposed SI curves.
  • Incorporation of covariate information using the covariate-specific SI curve.

Main Results:

  • The proposed estimators for the extended SI curve are shown to be consistent and asymptotically normal.
  • The covariate-specific SI curve effectively incorporates relevant patient characteristics into treatment selection evaluation.
  • Simulation studies and a cancer clinical trial application demonstrate the method's performance.

Conclusions:

  • The extended SI curve provides a valuable tool for evaluating biomarker-guided treatment selection in clinical practice.
  • The covariate-specific SI curve enhances personalized medicine by accounting for individual patient factors.
  • This methodology can improve treatment strategy optimization and patient outcomes in oncology and beyond.